AU2015257774B2 - Peptide vaccine comprising mutant RAS peptide and chemotherapeutic agent - Google Patents

Peptide vaccine comprising mutant RAS peptide and chemotherapeutic agent Download PDF

Info

Publication number
AU2015257774B2
AU2015257774B2 AU2015257774A AU2015257774A AU2015257774B2 AU 2015257774 B2 AU2015257774 B2 AU 2015257774B2 AU 2015257774 A AU2015257774 A AU 2015257774A AU 2015257774 A AU2015257774 A AU 2015257774A AU 2015257774 B2 AU2015257774 B2 AU 2015257774B2
Authority
AU
Australia
Prior art keywords
peptide
chemotherapeutic agent
substitution
seq
mutation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015257774A
Other languages
English (en)
Other versions
AU2015257774A1 (en
Inventor
Jon Amund Eriksen
Gustav Gaudernack
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Targovax Solutions AS
Original Assignee
Targovax Solutions AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50679896&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2015257774(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Targovax Solutions AS filed Critical Targovax Solutions AS
Publication of AU2015257774A1 publication Critical patent/AU2015257774A1/en
Application granted granted Critical
Publication of AU2015257774B2 publication Critical patent/AU2015257774B2/en
Assigned to Targovax Solutions AS reassignment Targovax Solutions AS Request for Assignment Assignors: TARGOVAX ASA
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001164—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2015257774A 2014-05-06 2015-05-05 Peptide vaccine comprising mutant RAS peptide and chemotherapeutic agent Ceased AU2015257774B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14167265.9 2014-05-06
EP14167265 2014-05-06
PCT/EP2015/059861 WO2015169804A1 (en) 2014-05-06 2015-05-05 Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent

Publications (2)

Publication Number Publication Date
AU2015257774A1 AU2015257774A1 (en) 2016-12-22
AU2015257774B2 true AU2015257774B2 (en) 2018-12-20

Family

ID=50679896

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015257774A Ceased AU2015257774B2 (en) 2014-05-06 2015-05-05 Peptide vaccine comprising mutant RAS peptide and chemotherapeutic agent

Country Status (16)

Country Link
US (1) US9757439B2 (https=)
EP (1) EP3140320B1 (https=)
JP (2) JP2017514847A (https=)
KR (1) KR20170002563A (https=)
CN (1) CN106414493A (https=)
AU (1) AU2015257774B2 (https=)
BR (1) BR112016025764A2 (https=)
CA (1) CA2947963A1 (https=)
CL (1) CL2016002794A1 (https=)
DK (1) DK3140320T3 (https=)
ES (1) ES2716923T3 (https=)
IL (1) IL248671B (https=)
MX (1) MX2016014414A (https=)
RU (1) RU2700929C2 (https=)
SG (2) SG11201608712PA (https=)
WO (1) WO2015169804A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3369432A1 (en) 2013-12-09 2018-09-05 Targovax Asa A peptide mixture
SG11201903674YA (en) 2016-10-26 2019-05-30 Modernatx Inc Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
JP2020514321A (ja) 2017-02-01 2020-05-21 モデルナティーエックス， インコーポレイテッド 活性化がん遺伝子変異ペプチドをコードする免疫調節治療ｍＲＮＡ組成物
WO2018145020A1 (en) * 2017-02-03 2018-08-09 The Medical College Of Wisconsin, Inc. Kras peptide vaccine compositions and method of use
BR112020025764A2 (pt) 2018-06-19 2021-05-11 Biontech Us Inc. neoantígenos e usos dos mesmos
WO2020002650A1 (en) 2018-06-29 2020-01-02 Targovax Asa A formulation
CN114681600A (zh) * 2018-10-19 2022-07-01 杭州纽安津生物科技有限公司 通用性多肽疫苗及其在制备治疗/预防胰腺癌药物中的应用
CA3141084A1 (en) * 2019-06-12 2020-12-17 Vikram JUNEJA Neoantigen compositions and uses thereof
CN113416241B (zh) * 2020-04-09 2022-04-08 北京臻知医学科技有限责任公司 一种用于诱导肿瘤特异性免疫响应的通用型抗原肽库及试剂盒
WO2022026620A1 (en) * 2020-07-29 2022-02-03 Sqz Biotechnologies Company Methods to stimulate immune responses to mutant ras using nucleated cells
EP4188425B1 (en) * 2020-07-29 2025-05-14 Stemcell Technologies Canada Inc. Methods to stimulate immune responses to mutant ras using anucleate cells
US20240000834A1 (en) * 2020-11-24 2024-01-04 Shanghai GenBase Biotechnology Co., Ltd. Ras mutant epitope peptide and t cell receptor recognizing ras mutant
JP2024541968A (ja) * 2021-10-28 2024-11-13 ジェネンテック， インコーポレイテッド 治療的介入のためにｍｈｃ関連抗原を同定するためのシステムおよび方法
WO2023220434A2 (en) * 2022-05-12 2023-11-16 The Johns Hopkins University Neoantigen vaccines for cancer prevention
WO2025103205A1 (en) * 2023-11-15 2025-05-22 Ck Life Sciences Development Limited Pharmaceutical compositions and methods for preventing or treating kras-associated diseases or conditions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9103974D0 (en) * 1991-02-26 1991-04-10 Norsk Hydro As Therapeutically useful peptides or peptide fragments
GB2328689A (en) 1997-08-27 1999-03-03 Norsk Hydro As Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer
NO309798B1 (no) * 1999-04-30 2001-04-02 Targovax As Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen
CN102370974B (zh) 2002-12-16 2014-09-17 全球免疫股份有限公司 用于免疫治疗的基于酵母的疫苗
US20140199405A1 (en) * 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on mutation status of k-ras
EP3369432A1 (en) 2013-12-09 2018-09-05 Targovax Asa A peptide mixture

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
STRIMPAKOS A S ET AL, "Update on phase I studies in advanced pancreatic adenocarcinoma. hunting in darkness?", JOURNAL OF THE PANCREAS 2013 vol. 14, no. 4, pages 354 - 358 *

Also Published As

Publication number Publication date
RU2016147527A3 (https=) 2019-01-21
AU2015257774A1 (en) 2016-12-22
US9757439B2 (en) 2017-09-12
MX2016014414A (es) 2017-02-23
EP3140320A1 (en) 2017-03-15
WO2015169804A1 (en) 2015-11-12
IL248671B (en) 2021-08-31
US20170065694A1 (en) 2017-03-09
BR112016025764A2 (pt) 2018-01-16
CN106414493A (zh) 2017-02-15
RU2700929C2 (ru) 2019-09-24
CA2947963A1 (en) 2015-11-12
JP7304629B2 (ja) 2023-07-07
CL2016002794A1 (es) 2017-06-09
KR20170002563A (ko) 2017-01-06
JP2017514847A (ja) 2017-06-08
IL248671A0 (en) 2017-01-31
SG11201608712PA (en) 2016-11-29
EP3140320B1 (en) 2018-12-26
RU2016147527A (ru) 2018-06-08
JP2020100650A (ja) 2020-07-02
SG10201809701TA (en) 2018-12-28
DK3140320T3 (en) 2019-04-15
ES2716923T3 (es) 2019-06-18

Similar Documents

Publication Publication Date Title
AU2015257774B2 (en) Peptide vaccine comprising mutant RAS peptide and chemotherapeutic agent
US9539299B2 (en) Combination therapy with WT1 peptide vaccine and temozolomide
CN118370809A (zh) 蛋白质抗原及其用途
AU2008292966B2 (en) Combination therapy for pancreatic cancer using an antigenic peptide and chemotherapeutic agent
Katakami et al. Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer
CN117813108A (zh) 基于肽的新抗原疫苗的多组分化学组合物
JP5435938B2 (ja) ワクチン接種のための天然ペプチド及びそれらの最適化された誘導体の使用
WO2018101831A1 (en) Pharmaceutical composition for use in the treatment of cancer
AU2017440798C1 (en) Improved treatment of cancer
HK1231899A1 (en) Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent
HK1231899B (en) Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent
US20230181633A1 (en) Methods of treating cancer using a combination of tumor membrane vesicles and metformin
WO2019197610A1 (en) New vaccinal strategy
WO2018088933A1 (en) Anti-tumor effects of a viral vector encoding a toll-like receptor and a toll-like receptor agonist
RU2773273C2 (ru) Неоантигены и способы их использования
TWI658832B (zh) 用於抑制骨髓衍生抑制細胞之組成物
JP2002356498A (ja) 滑膜肉腫抗原ペプチド
Katz et al. Survival efficacy of adjuvant cytosine analog CS-682 treatment of human pancreatic cancer in an orthotopic metastatic model monitored by fluorescence whole-body imaging

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: TARGOVAX SOLUTIONS AS

Free format text: FORMER OWNER(S): TARGOVAX ASA

MK14 Patent ceased section 143(a) (annual fees not paid) or expired